Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.

Internal medicine journal - 1 Jun 2014

Grey A, Cooper A, McNeil C, O'Toole S, Thompson J, Grimison P

Abstract excerpt

Vemurafenib is a tyrosine kinase inhibitor of BRAF that prolongs survival in patients with BRAF V600-mutant metastatic melanoma. Secondary cutaneous malignancies are a well-documented toxicity of vemurafenib, thought to be mediated by enhanced ERK signalling in BRAF wild-type, RAS-mutant cells. Vemurafenib could also promote growth of non-cutaneous secondary malignancies by a similar mechanism. We present a case...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Chemoradiotherapy
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Neoplasms, Second Primary

Share to Positron-Emission Tomography

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 24946815
DOI: 10.1111/imj.12415

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.PMID 24946815Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.Semantic proximity Read ↗

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Semantic proximity Read ↗

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.Semantic proximity Read ↗

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.